Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMO0SU)

Drug Name
Dersimelagon Drug Info
Synonyms
Dersimelagon; 1835256-48-8; Dersimelagon [INN]; Dersimelagon [USAN]; MT-7117; 1CWH5SV4G2; 1-(2-((3S,4R)-1-((3R,4R)-1-Cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl)-4-(methoxymethyl)pyrrolidin-3-yl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylic acid; Dersimelagon [USAN:INN]; UNII-1CWH5SV4G2; DERSIMELAGON [WHO-DD]; CHEMBL4802160; SCHEMBL18686769; MUNWOYRHJPWQNE-GMFUQMJFSA-N; WHO 10832; AKOS040746751; AC-36942; HY-109114; CS-0077733; 4-PIPERIDINECARBOXYLIC ACID, 1-(2-((3S,4R)-1-(((3R,4R)-1-CYCLOPENTYL-3-FLUORO-4-(4-METHOXYPHENYL)-3-PYRROLIDINYL)CARBONYL)-4-(METHOXYMETHYL)-3-PYRROLIDINYL)-5- (TRIFLUOROMETHYL)PHENYL)-
Indication
Disease Entry ICD 11 Status REF
Erythropoietic protoporphyria 5C58.12 Phase 3 [1]
Cross-matching ID
PubChem CID
126736894
TTD Drug ID
DMMO0SU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melanocortin receptor 1 (MC1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [3]
Afamelanotide DMVWHTG Erythropoietic porphyrias 5C58.12 Approved [4]
PL8177 DML5V22 Ulcerative colitis DD71 Phase 2 [5]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [6]
MT-II DMKT1DA Female sexual arousal dysfunction HA01.1 Investigative [7]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO Discovery agent N.A. Investigative [8]
Ac-YRMEHdFRWG-NH2 DMN2UKC Discovery agent N.A. Investigative [9]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ Discovery agent N.A. Investigative [8]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW Discovery agent N.A. Investigative [8]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocortin receptor 1 (MC1R) TT0MV2T MSHR_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT04402489) A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria. U.S.National Institutes of Health.
2 Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022 Sep 1;24(1):210.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration. Drugs R D. 2021 Dec;21(4):431-443.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9.
8 Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
9 Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.